Related Experiment Video

Updated: Aug 13, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma

Daniel A Morgenstern1, John Anderson

  • 1Northwick Park Hospital, Harrow, HA1 3UJ, UK. dam1003@cam.ac.uk

Expert Review of Anticancer Therapy
|February 1, 2006
PubMed

Insights

New strategies targeting the MYCN oncogene offer hope for treating high-risk rhabdomyosarcoma, especially the alveolar subtype. This review explores novel nucleic acid and immunotherapy approaches for this challenging childhood cancer.

Area of Science:

  • Pediatric Oncology
  • Molecular Oncology
  • Cancer Therapeutics

Background:

  • Rhabdomyosarcoma is the most frequent soft-tissue sarcoma in children.
  • Current treatments combining chemotherapy, surgery, and radiotherapy have improved outcomes, but high-risk and alveolar subtypes still have poor prognoses.
  • There is a critical need for novel therapeutic strategies for these aggressive forms of rhabdomyosarcoma.

Purpose of the Study:

  • To review the potential of targeting the MYCN oncogene in rhabdomyosarcoma.
  • To highlight the role of MYCN deregulation in alveolar rhabdomyosarcoma.
  • To discuss emerging therapeutic interventions against MYCN.

Main Methods:

  • Review of current literature on MYCN's role in rhabdomyosarcoma.
  • Analysis of therapeutic strategies targeting MYCN.
  • Exploration of nucleic acid-based and immunotherapy approaches.

Main Results:

  • MYCN oncogene deregulation is implicated in up to 25% of alveolar rhabdomyosarcoma cases.
  • Targeting MYCN presents a promising avenue for novel chemotherapeutic strategies.
  • Various approaches, including nucleic acid therapies and immunotherapies, are being investigated.

Conclusions:

  • Targeting MYCN offers a potential new therapeutic direction for high-risk rhabdomyosarcoma, particularly the alveolar subtype.
  • Further research into MYCN-directed therapies is warranted to improve patient outcomes.
  • Developing novel treatments is crucial for addressing the unmet needs in pediatric rhabdomyosarcoma care.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...